Arnold Oliphant joined Omniome in 2017 as the CTO, and is responsible for leading the research and development of Omniome’s sequencing technology. Arnold has a varied background in developing DNA technologies and their diagnostic applications. Most recently, as the CSO of Ariosa, he led the development of the Harmony NIPT test. Prior to Ariosa, Arnold was the VP of Scientific Operations at Complete Genomics where he led the teams responsible for developing DNA Nano balls and the CPAL sequencing process that produced the most accurate human genome at the time. Before joining Complete Genomics, Arnold was the VP of Scientific Operations at Illumina where he led the team that developed the Golden Gate genotyping assay and the Infinium genotyping assay, the first highly multiplexed genotyping assay capable of genotyping millions of loci simultaneously, now used by 23andMe. Prior to Illumina, Arnold was the VP of Functional Genomics at Myriad Genetics where he led the development of the BRCA1 and BRCA2 diagnostic DNA sequencing test for the predisposition of breast cancer.

Arnold holds a PhD in Genetics from Harvard Medical School and a BA in Genetics from the University of Utah.